Over 25,000 people begin Wegovy each week, a significant increase from around 5,000 new users a week in December.
Novo Nordisk reported a 22% sales increase in the first quarter, with Ozempic sales rising 42% and Wegovy sales skyrocketing 106%.
The company lowered its outlook for 2024 due to lower prices and increased competition from rivals such as Eli Lilly's weight loss drug, Mounjaro.
Novo Nordisk and Eli Lilly are facing challenges in meeting the rising demand for their drugs amid supply shortages, with increased production efforts underway.
[
add
]
[
|
|
...
]